Atlas Trials

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Clinical trial NCT06991556 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06991556
Sponsor
Novartis Pharmaceuticals
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Hormone-sensitive Prostate Cancer
Start date
2025-07-07
Primary completion
2032-02-13
Enrollment
165

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.